Clinical trial
To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis…
NCT00050661 · Rockefeller University, Other · Completed
Key facts
| NCT number | NCT00050661 |
|---|---|
| Title | To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris |
| Official title | Use of Humanized CD25 (Anti-TAC) Monoclonal Antibody/ Placebo to Prevent Relapse of Psoriasis Vulgaris Following NBUVB Therapy |
| Lead sponsor | Rockefeller University, Other |
| Collaborators | Facet Biotech Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Device, Drug |
| Interventions | Daclizumab, NB-UVB |
| Enrollment | 6 |
| Start date | Oct 1, 1997 |
| Primary completion | Apr 1, 2004 |
| Completion | Apr 1, 2008 |
| First posted | Dec 18, 2002 |
| Last update posted | Mar 25, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: